Clinical trials: Dermatitis Eczema
Atopic Dermatitis
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates safety and efficacy of 1.1% w/w AMTX-100 CF versus placebo (vehicle).
- Trial name
- NCT04313400
- Testing
- 1.1% w/w AMTX-100 CF-part1, 1.1% w/w AMTX-100 CF3-part2
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Amytrx Therapeutics, Inc.
Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-2 (NCT03575871)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at…
- Trial name
- NCT00919763
- Testing
- CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
- Where
- 14 sites in United States
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Impetigo, Folliculitis
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections…
- Conditions
- Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
- Trial name
- NCT01126268
- Testing
- Retapamulin (Altabax)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- The University of Texas Health Science Center, Houston
Dermatitis, Atopic
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04990440
- Testing
- Bermekimab
- Where
- 11 sites in United States, Argentina
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema
This three week study will be conducted to determine the safety and efficacy of an over-the-counter (OTC) cream in children with mild to moderate atopic dermatitis.
- Trial name
- NCT01326910
- Testing
- Colloidal Oatmeal, Topical Cream
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03363854
- Testing
- Tralokinumab
- Where
- 66 sites in United States, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- LEO Pharma
Eczema, Egg Allergy
Persistence of Oral Tolerance to Peanut
ITN049AD (LEAP-On) Study is a continuation of the ITN032AD LEAP Study (NCT00329784). Peanut Allergy, a recognized public health concern, is a common and potentially life-threatening food allergy for which there is no treatment.
- Conditions
- Eczema, Egg Allergy, Food Allergy, Hypersensitivity
- Trial name
- LEAP-On (NCT01366846)
- Testing
- Avoidance of peanut
- Where
- United Kingdom
- Volunteers
- 556 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis Eczema
8-Week Atopic Dermatitis (AD) Treatment Study
This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
- Trial name
- NCT03386032
- Testing
- Investigational OTC Cream, 0.05% Desonide
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Procter and Gamble
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic, Eczema
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT04800315
- Testing
- CC-93538
- Where
- 157 sites in United States, Canada and 4 more
- Volunteers
- 221 people
- Sponsor
- Celgene
Dermatitis, Atopic
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.
- Trial name
- NCT01652885
- Testing
- AN2728 Topical Ointment, 2%
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Atopic Dermatitis
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
- Trial name
- NCT02945657
- Testing
- MM36 topical ointment, 1%
- Where
- 12 sites in United States, Honduras and 1 more
- Volunteers
- 32 people
- Sponsor
- Medimetriks Pharmaceuticals, Inc
Atopic Dermatitis
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Flex-Up (NCT05507580)
- Testing
- Upadacitinib
- Where
- 106 sites in Australia, Belgium and 16 more
- Volunteers
- 461 people
- Sponsor
- AbbVie
Atopic Dermatitis
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
This single blind study is to primarily evaluate wearable devices and Observer Reported Itch Assessment in children to assess reduction of itch and night-time scratch in response to Crisaborole treatment vs.
- Trial name
- PAD (NCT05200403)
- Testing
- Crisaborole 2%, Vehicle treatment, Accelerometry device for children
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Boston University
Atopic Dermatitis
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
- Trial name
- SCRATCH-AD (NCT04839380)
- Testing
- ruxolitinib cream
- Where
- 2 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation